Loading
Kernal Biologics
Kernal Bio designs mRNA medicines that switch on only in the intended cell type, for example programming a patient's T cells against cancer inside the body without taking them out first.
Overview
Kernal Biologics develops cell-selective mRNA therapeutics: mRNA engineered to translate only in chosen cell types, delivered in lipid nanoparticles targeted to those cells. Its KR-402 programme uses T-cell-targeted particles to programme CAR-T cells in vivo and, per the company, achieves over 90 percent delivery efficiency with B-cell depletion within a week in preclinical models. Oncology applications include in vivo CAR-T and immune-stimulating mRNA for solid tumours. The company's YC profile names Hummingbird Ventures, Amgen Ventures, HBM and NASA among its backers; work is preclinical.
Headquarters
Cambridge, MA, US
Funding
All startupsStartupYC S20
Investors
Type
Stage
Startup · Y Combinator Summer 2020
Website
Connected
7Similar pages
- CompanyTareBio
Shares Y Combinator, Personalised neoantigen (mRNA) vaccines and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator and the tag yc.
fronts
technologies
targets
companies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
kernalbio.com · 1
ycombinator.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/